GLP1R and metabolic dysfunction-associated steatohepatitis: GCGR/GLP-1R dual agonists consistently showed improvements in NASH and fibrosis in various animal models [48,85,86]; the dual GCGR/GLP-1R agonist G49 demonstrated beneficial effects in MCD diet-induced NASH fibrosis and upon partial hepatectomy in DIO mice, respectively [86].